Cargando…
A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia
INTRODUCTION: This study aimed to gather a range of opinions, including those of affected people (consumers, concerned others) to identify clinical research priorities for methamphetamine and emerging drugs of concern in Australia, to guide the work of the National Centre for Clinical Research on Em...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290984/ https://www.ncbi.nlm.nih.gov/pubmed/34237176 http://dx.doi.org/10.1111/dar.13350 |
_version_ | 1784749036063948800 |
---|---|
author | Siefried, Krista J. Ezard, Nadine Christmass, Michael Haber, Paul Ali, Robert |
author_facet | Siefried, Krista J. Ezard, Nadine Christmass, Michael Haber, Paul Ali, Robert |
author_sort | Siefried, Krista J. |
collection | PubMed |
description | INTRODUCTION: This study aimed to gather a range of opinions, including those of affected people (consumers, concerned others) to identify clinical research priorities for methamphetamine and emerging drugs of concern in Australia, to guide the work of the National Centre for Clinical Research on Emerging Drugs (NCCRED). METHODS: A priority setting study was conducted (February–March 2019) in four phases: online stakeholder survey, thematic analysis of responses, rapid literature review, expert panel ranking of priorities against predetermined criteria. RESULTS: Forty‐seven respondents completed the survey, including people identifying as one or more of: researcher (53%, n = 25), clinician (45%; n = 21), family/friend/caregiver of someone who uses methamphetamine/emerging drugs (15%, n = 7) and consumer of methamphetamine/emerging drugs (13%, n = 6). Expert panel, evidence‐informed top‐ranked clinical research priorities for methamphetamine were: strategies to overcome barriers to intervention uptake, pilot medication trials for adults seeking treatment, and communication strategies regarding evidence‐based treatments. For emerging drugs of concern, top‐ranked priorities were: piloting community‐located drug checking, feasibility of social media/other opportunities to alert consumers of emerging risks, GHB overdose and withdrawal management, and impacts of an early warning information system on reducing harms. DISCUSSION AND CONCLUSIONS: We demonstrate feasibility of a structured, collaborative clinical research priority setting process. Results have informed the establishment of NCCRED; using the identified priorities to guide seed funding, fellowships/scholarships and research programs. Broader uptake of this methodology by policymakers/research funders would assist to embed areas of concern identified by affected communities and other stakeholders in research prioritisation. |
format | Online Article Text |
id | pubmed-9290984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-92909842022-07-20 A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia Siefried, Krista J. Ezard, Nadine Christmass, Michael Haber, Paul Ali, Robert Drug Alcohol Rev Original Papers INTRODUCTION: This study aimed to gather a range of opinions, including those of affected people (consumers, concerned others) to identify clinical research priorities for methamphetamine and emerging drugs of concern in Australia, to guide the work of the National Centre for Clinical Research on Emerging Drugs (NCCRED). METHODS: A priority setting study was conducted (February–March 2019) in four phases: online stakeholder survey, thematic analysis of responses, rapid literature review, expert panel ranking of priorities against predetermined criteria. RESULTS: Forty‐seven respondents completed the survey, including people identifying as one or more of: researcher (53%, n = 25), clinician (45%; n = 21), family/friend/caregiver of someone who uses methamphetamine/emerging drugs (15%, n = 7) and consumer of methamphetamine/emerging drugs (13%, n = 6). Expert panel, evidence‐informed top‐ranked clinical research priorities for methamphetamine were: strategies to overcome barriers to intervention uptake, pilot medication trials for adults seeking treatment, and communication strategies regarding evidence‐based treatments. For emerging drugs of concern, top‐ranked priorities were: piloting community‐located drug checking, feasibility of social media/other opportunities to alert consumers of emerging risks, GHB overdose and withdrawal management, and impacts of an early warning information system on reducing harms. DISCUSSION AND CONCLUSIONS: We demonstrate feasibility of a structured, collaborative clinical research priority setting process. Results have informed the establishment of NCCRED; using the identified priorities to guide seed funding, fellowships/scholarships and research programs. Broader uptake of this methodology by policymakers/research funders would assist to embed areas of concern identified by affected communities and other stakeholders in research prioritisation. John Wiley & Sons Australia, Ltd 2021-07-08 2022-02 /pmc/articles/PMC9290984/ /pubmed/34237176 http://dx.doi.org/10.1111/dar.13350 Text en © 2021 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Papers Siefried, Krista J. Ezard, Nadine Christmass, Michael Haber, Paul Ali, Robert A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia |
title | A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia |
title_full | A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia |
title_fullStr | A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia |
title_full_unstemmed | A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia |
title_short | A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia |
title_sort | clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in australia |
topic | Original Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290984/ https://www.ncbi.nlm.nih.gov/pubmed/34237176 http://dx.doi.org/10.1111/dar.13350 |
work_keys_str_mv | AT siefriedkristaj aclinicalresearchprioritysettingstudyforissuesrelatedtotheuseofmethamphetamineandemergingdrugsofconcerninaustralia AT ezardnadine aclinicalresearchprioritysettingstudyforissuesrelatedtotheuseofmethamphetamineandemergingdrugsofconcerninaustralia AT christmassmichael aclinicalresearchprioritysettingstudyforissuesrelatedtotheuseofmethamphetamineandemergingdrugsofconcerninaustralia AT haberpaul aclinicalresearchprioritysettingstudyforissuesrelatedtotheuseofmethamphetamineandemergingdrugsofconcerninaustralia AT alirobert aclinicalresearchprioritysettingstudyforissuesrelatedtotheuseofmethamphetamineandemergingdrugsofconcerninaustralia AT aclinicalresearchprioritysettingstudyforissuesrelatedtotheuseofmethamphetamineandemergingdrugsofconcerninaustralia AT siefriedkristaj clinicalresearchprioritysettingstudyforissuesrelatedtotheuseofmethamphetamineandemergingdrugsofconcerninaustralia AT ezardnadine clinicalresearchprioritysettingstudyforissuesrelatedtotheuseofmethamphetamineandemergingdrugsofconcerninaustralia AT christmassmichael clinicalresearchprioritysettingstudyforissuesrelatedtotheuseofmethamphetamineandemergingdrugsofconcerninaustralia AT haberpaul clinicalresearchprioritysettingstudyforissuesrelatedtotheuseofmethamphetamineandemergingdrugsofconcerninaustralia AT alirobert clinicalresearchprioritysettingstudyforissuesrelatedtotheuseofmethamphetamineandemergingdrugsofconcerninaustralia AT clinicalresearchprioritysettingstudyforissuesrelatedtotheuseofmethamphetamineandemergingdrugsofconcerninaustralia |